Feb 7, 2019 by Brian Orelli, PhDVertex Pharmaceuticals: New Drug, Same Great Growth StoryThe biotech continues to make inroads in cystic fibrosis.
Feb 7, 2019 by Brian Orelli, PhDQIAGEN Continues to TransformWith new products, growth at the diagnostic test company is set to accelerate this year.
Feb 6, 2019 by Brian Orelli, PhDWhy ImmunoGen Jumped Almost 14% TodayData is coming for the biotech's lead program.
Feb 5, 2019 by Brian Orelli, PhDNovo Nordisk Is on the Upswing -- for NowThe full year may be a different story.
Feb 4, 2019 by Brian Orelli, PhDCelgene Highlights What Bristol-Myers Squibb Is GettingIt was a solid fourth quarter as the company looks to hand over the reins.
Jan 31, 2019 by Brian Orelli, PhDHere's Why Moderna Jumped 9.7% on ThursdayThe company's drug cures cancer in mice.
Jan 30, 2019 by Brian Orelli, PhDBiogen Looks to 20202018 wasn't too bad, but don't expect much in 2019
Jan 29, 2019 by Brian Orelli, PhDThe Biggest Biotech Binary Event in 2019 Is Just Around the CornerInvestors, mark your calendars.
Jan 24, 2019 by Brian Orelli, PhDModerna's Hot New mRNA Technology Has CompetitionThey're largely flying under the radar of most investors.
Jan 24, 2019 by Brian Orelli, PhDWhere Will bluebird bio Be in 5 Years?Looking ahead is the only way to value this biotech.
Jan 18, 2019 by Brian Orelli, PhDHere's Why Tyme Technologies Fell 35% on FridayThe devil is in the clinical-trial details.
Jan 18, 2019 by Brian Orelli, PhDHere's Why Immunomedics Plummeted on FridayThe FDA sent the biotech back to the drawing board.
Jan 17, 2019 by Brian Orelli, PhD1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet)Revenue growth is key.
Jan 16, 2019 by Brian Orelli, PhDHere's Why Ligand Pharmaceuticals Plummeted 16% TodayWhen Citron speaks, investors listen -- but should they?
Jan 14, 2019 by Brian Orelli, PhDHere's Why Marijuana Stock Insys Therapeutics Fell More Than 63% in 2018The opioid business isn't what it used to be.
Jan 9, 2019 by Brian Orelli, PhDHere's Why NeoGenomics Rocketed Higher TodayIt was nothing the medical diagnostics company did.
Jan 8, 2019 by Brian Orelli, PhD3 Things Alnylam's Management Wants You to KnowThe biotech gave investors reasons to cheer at the J.P. Morgan Healthcare Conference
Jan 7, 2019 by Brian Orelli, PhDHere's Why Insmed Rocketed 43% Higher on MondayInvestors are impressed with early sales numbers for the biotech's Arikayce antibiotic.
Jan 7, 2019 by Brian Orelli, PhDHere's Why Diplomat Pharmacy Slipped 10.5% on MondayThe company's PBM business isn't paying off yet.
Jan 6, 2019 by Brian Orelli, PhDAll the Pre-JPM News Healthcare Investors Need to KnowThe Super Bowl of biotech kicked off early for these companies.
![gbbppba0uila000006[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F508082%2Fgbbppba0uila0000061.jpg&w=384&op=resize)
![f0420e49ba81382694712e6d2ad925c9[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F507530%2Ff0420e49ba81382694712e6d2ad925c91.png&w=384&op=resize)
